Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

Yucai Wang, Reem Karmali, Steven R. Hwang et al.|Blood|2023

Cited by 10